Keywords: GlaxoSmithKline, Votrient, Scotland, Kidney cancer

GlaxoSmithKline’s Votrient OKed for NHS Scotland use in kidney cancer

Article | 08 March 2011

Print This

The Scottish Medicines Consortium (SMC) has issued advice to NHS Scotland on the use of UK drug giant GlaxoSmithKline’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in